| Primary |
| Acute Myeloid Leukaemia |
67.9% |
| Acute Monocytic Leukaemia |
4.9% |
| Acute Lymphocytic Leukaemia |
4.6% |
| Acute Promyelocytic Leukaemia |
4.6% |
| Lymphocytic Leukaemia |
2.6% |
| Prophylaxis |
2.0% |
| Streptococcal Sepsis |
2.0% |
| Antiemetic Supportive Care |
1.3% |
| Sepsis |
1.3% |
| Stem Cell Transplant |
1.3% |
| Vomiting |
1.3% |
| Hyperpyrexia |
1.0% |
| Hyperuricaemia |
1.0% |
| Acute Leukaemia |
0.7% |
| Coronary Arterial Stent Insertion |
0.7% |
| Gastritis Prophylaxis |
0.7% |
| Multiple Myeloma |
0.7% |
| Prophylaxis Of Nausea And Vomiting |
0.7% |
| Psoriatic Arthropathy |
0.7% |
| Acute Myeloid Leukaemia (In Remission) |
0.3% |
|
| Stomatitis |
10.4% |
| Pulmonary Mycosis |
9.0% |
| Septic Shock |
9.0% |
| Vomiting |
7.5% |
| Enterococcal Sepsis |
6.0% |
| Pancreatitis Acute |
6.0% |
| Staphylococcal Sepsis |
6.0% |
| Stomatitis Necrotising |
6.0% |
| Epididymitis |
4.5% |
| Palatal Oedema |
4.5% |
| Pneumocystis Jiroveci Pneumonia |
4.5% |
| Drug Effect Prolonged |
3.0% |
| Escherichia Sepsis |
3.0% |
| Febrile Neutropenia |
3.0% |
| Hepatotoxicity |
3.0% |
| Hypertransaminasaemia |
3.0% |
| Neoplasm Malignant |
3.0% |
| Neutropenic Colitis |
3.0% |
| Pleural Effusion |
3.0% |
| Pneumonia |
3.0% |
|
| Secondary |
| Acute Myeloid Leukaemia |
51.6% |
| Product Used For Unknown Indication |
10.9% |
| Drug Use For Unknown Indication |
5.9% |
| Acute Lymphocytic Leukaemia |
5.7% |
| Prophylaxis |
5.3% |
| Pyrexia |
3.7% |
| Chronic Myeloid Leukaemia |
2.7% |
| Vomiting |
2.0% |
| Acute Promyelocytic Leukaemia |
1.6% |
| Acute Myeloid Leukaemia Recurrent |
1.4% |
| Myeloid Leukaemia |
1.2% |
| Acute Myeloid Leukemia |
1.0% |
| Chronic Myeloid Leukaemia Transformation |
1.0% |
| Ascites |
0.8% |
| Bacteraemia |
0.8% |
| Blood Potassium Decreased |
0.8% |
| Fungal Test Positive |
0.8% |
| Herpes Simplex |
0.8% |
| Histiocytosis Haematophagic |
0.8% |
| Oedema |
0.8% |
|
| Septic Shock |
15.1% |
| Pancreatitis Acute |
12.3% |
| Sepsis |
12.3% |
| Staphylococcal Sepsis |
8.2% |
| Myocardial Infarction |
5.5% |
| Hepatic Steatosis |
4.1% |
| Pericardial Effusion |
4.1% |
| Respiratory Distress |
4.1% |
| Thrombocytopenia |
4.1% |
| Bilirubin Conjugated Increased |
2.7% |
| Condition Aggravated |
2.7% |
| Disease Progression |
2.7% |
| Hepatic Failure |
2.7% |
| Hypertransaminasaemia |
2.7% |
| Jaundice |
2.7% |
| Pleurisy |
2.7% |
| Pneumonia Fungal |
2.7% |
| Pulmonary Alveolar Haemorrhage |
2.7% |
| Skin Necrosis |
2.7% |
| Stomatitis |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.1% |
| Acute Myeloid Leukaemia |
18.8% |
| Acute Promyelocytic Leukaemia |
5.8% |
| Neoplasm Malignant |
5.8% |
| Acute Lymphocytic Leukaemia |
4.3% |
| Aspergillosis |
4.3% |
| Oesophagitis |
4.3% |
| Agranulocytosis |
2.9% |
| Antiallergic Therapy |
2.9% |
| Antibiotic Therapy |
2.9% |
| Antifungal Prophylaxis |
2.9% |
| Drug Use For Unknown Indication |
2.9% |
| Gout |
2.9% |
| Prophylaxis |
2.9% |
| Vomiting |
2.9% |
| Anaemia |
1.4% |
| Antacid Therapy |
1.4% |
| Aplastic Anaemia |
1.4% |
| Blood Immunoglobulin G |
1.4% |
| Bone Marrow Failure |
1.4% |
|
| Retinoic Acid Syndrome |
16.7% |
| Rash |
8.3% |
| Septic Shock |
8.3% |
| Confusional State |
4.2% |
| Cytolytic Hepatitis |
4.2% |
| Drug Ineffective For Unapproved Indication |
4.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.2% |
| Drug-induced Liver Injury |
4.2% |
| Febrile Bone Marrow Aplasia |
4.2% |
| Hyperpyrexia |
4.2% |
| Joint Swelling |
4.2% |
| Long Qt Syndrome |
4.2% |
| Pain In Jaw |
4.2% |
| Renal Failure Chronic |
4.2% |
| Sepsis |
4.2% |
| Speech Disorder |
4.2% |
| Tachycardia |
4.2% |
| Thrombosis |
4.2% |
| Urticaria |
4.2% |
|
| Interacting |
| Acute Myeloid Leukaemia |
100.0% |
|
| Pulmonary Haemorrhage |
100.0% |
|
